Invesco Ltd. Buys 4,942 Shares of Amedisys, Inc. (NASDAQ:AMED)

Invesco Ltd. boosted its holdings in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 5.8% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 90,847 shares of the health services provider's stock after acquiring an additional 4,942 shares during the period. Invesco Ltd. owned 0.28% of Amedisys worth $8,248,000 as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in the stock. Wells Fargo & Company MN boosted its holdings in Amedisys by 4.7% during the fourth quarter. Wells Fargo & Company MN now owns 7,161 shares of the health services provider's stock worth $650,000 after buying an additional 323 shares during the last quarter. Resona Asset Management Co. Ltd. bought a new position in Amedisys during the 4th quarter worth approximately $535,000. ExodusPoint Capital Management LP acquired a new position in Amedisys during the fourth quarter valued at approximately $356,000. Cinctive Capital Management LP bought a new stake in Amedisys in the fourth quarter valued at approximately $8,155,000. Finally, Trexquant Investment LP raised its holdings in Amedisys by 1,317.8% in the fourth quarter. Trexquant Investment LP now owns 87,719 shares of the health services provider's stock worth $7,964,000 after purchasing an additional 81,532 shares during the period. Institutional investors and hedge funds own 94.36% of the company's stock.

Analyst Ratings Changes

AMED has been the subject of a number of recent analyst reports. Stephens restated an "equal weight" rating and issued a $101.00 price objective on shares of Amedisys in a research report on Tuesday, March 4th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $100.00 price target on shares of Amedisys in a research report on Wednesday, April 16th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $100.75.

Amedisys Stock Up 0.2 %

Shares of Amedisys stock traded up $0.23 during trading on Friday, reaching $94.50. The stock had a trading volume of 361,426 shares, compared to its average volume of 406,625. The stock has a fifty day moving average price of $92.21 and a two-hundred day moving average price of $91.79. Amedisys, Inc. has a 52 week low of $82.15 and a 52 week high of $98.95. The company has a market capitalization of $3.10 billion, a price-to-earnings ratio of 37.50, a P/E/G ratio of 1.78 and a beta of 0.89. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMED - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.12. The firm had revenue of $594.78 million for the quarter, compared to analyst estimates of $597.43 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. Sell-side analysts predict that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.